For the neoadjuvant goal of debulking a macroscopic primary tumor, which is likely to be heterogeneous in its PSMA expression, the longer range and cross-fire effect of a β-emitter like 177Lu may be more beneficial [50]. Here, FOLH1 is linked to neoplasm.